Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies

Purpose: The KRAS proto-oncogene is involved in the RAS/MAPK pathway. KRAS is present in the wild type or mutated forms. The oncogene KRAS is frequently mutated in various cancers. At the time that amino acid glycine is mutated, KRAS protein acquires oncogenic properties that result in the tumor cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardalan, Bach, Azqueta, Jose, Sleeman, Danny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655806/
https://www.ncbi.nlm.nih.gov/pubmed/34901697
http://dx.doi.org/10.1089/pancan.2021.0006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655806/
https://www.ncbi.nlm.nih.gov/pubmed/34901697
http://dx.doi.org/10.1089/pancan.2021.0006

Ejemplares similares